Search Results
Showing Results for targetable
What’s new in GI oncology? With the 2025 ASCO Gastrointestinal Cancers Symposium still fresh in our minds, we hear from leading experts on the key abstracts and presentations from the conference in the fields of colorectal and pancreatic cancer. Circulating ...
Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The ...
Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (...
The management of children with diffuse midline gliomas (DMG) and other paediatric high-grade gliomas (pHGG) continue to present one of the most difficult challenges facing paediatric oncologists, characterized by poor patient outcomes.1Â Standard of care therapy, which includes a maximal ...
Acute myeloid leukaemia (AML) is a heterogeneous haematological malignancy characterized by the presence of ≥20% blasts in bone marrow or peripheral blood or the presence of defined genetic abnormalities.1 In 2020, there were an estimated 21,450 new patients with AML and 11,180 AML-related deaths ...
Triple-negative breast cancer (TNBC) is a biologically aggressive form of breast cancer defined by the absence of the oestrogen receptor and progesterone receptor, as well as lack of amplification of the human epidermal growth factor receptor 2 (HER2). TNBC accounts for ...
Gastro-oesophageal cancers (GEC), which include both gastric (GC) and oesophageal cancers (EC), are among the most common cancers globally.1Â In the USA, the American Cancer Society estimated 20,640 new diagnoses of EC and 26,380 new diagnoses of GC, each contributing to 16,410 and 11,090 ...
Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. While they account for around 3% of all gastrointestinal malignancies, they are the second most common primary liver cancer.1Â CCAs tend to metastasize and have early lymph node ...
Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive ...
In 2020, an estimated 147,950 patients will be diagnosed with colorectal cancer (CRC) in the USA, with 53,200 deaths expected.1 While many patients with CRC are cured, metastatic CRC (mCRC) is still a prevalent disease, and systemic therapy options have markedly improved outcomes ...
Welcome to the spring edition of Oncology and Hematology Review (US). During the difficult days of this COVID-19 pandemic, which has impacted cancer care worldwide, we hope our journal provides reason for optimism. We begin with one of our popular ...
Cholangiocarcinoma constitutes approximately 3% of all gastrointestinal malignancies, and the incidence is on the rise, especially the intrahepatic subtype. These tumors are anatomically broadly classified into intrahepatic, perihilar, and distal cholangiocarcinoma. Recent understanding of tumorigenesis pathways has shown that there exists ...
Maurice Pérol, M.D., was Associate Professor of Pneumology and Head of the Department of Thoracic Oncology at the Croix-Rousse University Hospital in Lyon, France from 1993 until 2011. In 2011, he joined the Medical Oncology Department of Léon Bérard ...
Advances in understanding of the molecular processes underlying non-small cell lung cancer (NSCLC) have led to the identification of several specific targets for therapeutic agents. To date, the most beneficial therapies targeting gene rearrangements are those that target the ALK, ...
Bladder cancer is the ninth most common cancer worldwide, with an estimated 430,000 new cases and 165,000 deaths in 2012.1 More than 90% of bladder cancers are of urothelial cell origin and the remaining histological subtypes include either pure forms of histological variants, such ...
Insights into the KEYNOTE-189 Study presented at American Association for Cancer Research Annual Meeting, Chicago, IL, US, April 14–18, 2018. The use of immune checkpoint inhibitors has transformed the management of non-small cell lung cancer (NSCLC). Until recently, platinum-based chemotherapy was the ...
Over the course of the last three decades there has been significant improvement in the outcomes of children with non-Hodgkin lymphoma (NHL).1 However, despite varied treatment strategies and sequential clinical trials, the prognosis for one NHL subtype, anaplastic large cell ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
